120 related articles for article (PubMed ID: 10627645)
41. Intravenous busulfan and melphalan, tacrolimus, and short-course methotrexate followed by unmodified HLA-matched related or unrelated hematopoietic stem cell transplantation for the treatment of advanced hematologic malignancies.
Small TN; Young JW; Castro-Malaspina H; Prockop S; Wilton A; Heller G; Boulad F; Chiu M; Hsu K; Jakubowski A; Kernan NA; Perales MA; O'Reilly RJ; Papadopoulos EB
Biol Blood Marrow Transplant; 2007 Feb; 13(2):235-44. PubMed ID: 17241929
[TBL] [Abstract][Full Text] [Related]
42. Impact of conditioning regimen intensity on outcome of allogeneic hematopoietic cell transplantation for advanced acute myelogenous leukemia and myelodysplastic syndrome.
Alyea EP; Kim HT; Ho V; Cutler C; DeAngelo DJ; Stone R; Ritz J; Antin JH; Soiffer RJ
Biol Blood Marrow Transplant; 2006 Oct; 12(10):1047-55. PubMed ID: 17067911
[TBL] [Abstract][Full Text] [Related]
43. [Genetic diagnosis of leukemia: diagnosis of relapse and complete remission, and prediction of leukemia onset].
Sugiyama H
Rinsho Byori; 2000 Feb; 48(2):155-61. PubMed ID: 10804819
[TBL] [Abstract][Full Text] [Related]
44. Donor cell myelodysplastic syndrome after allogeneic stem cell transplantation responding to donor lymphocyte infusion: case report and literature review.
Komrokji R; Ifthikharuddin JJ; Felgar RE; Abboud CN; Wedow LA; Connaughton A; Bennett JM
Am J Hematol; 2004 Aug; 76(4):389-94. PubMed ID: 15282676
[TBL] [Abstract][Full Text] [Related]
45. Alternatives to conventional or myeloablative chemotherapy in myelodysplastic syndrome.
Cazzola M
Int J Hematol; 2000 Aug; 72(2):134-8. PubMed ID: 11039660
[TBL] [Abstract][Full Text] [Related]
46. Significant correlation between the degree of WT1 expression and the International Prognostic Scoring System Score in patients with myelodysplastic syndromes.
Cilloni D; Gottardi E; Messa F; Fava M; Scaravaglio P; Bertini M; Girotto M; Marinone C; Ferrero D; Gallamini A; Levis A; Saglio G;
J Clin Oncol; 2003 May; 21(10):1988-95. PubMed ID: 12743153
[TBL] [Abstract][Full Text] [Related]
47. Thiotepa/cyclophosphamide/TBI as a conditioning regimen for allogeneic hematopoietic stem cell transplantation in patients with myelodysplastic syndrome.
Fujimaki K; Taguchi J; Fujita H; Hattori M; Yamazaki E; Takahashi N; Fujisawa S; Kanamori H; Maruta A; Ishigatsubo Y
Bone Marrow Transplant; 2004 Apr; 33(8):789-92. PubMed ID: 15064685
[TBL] [Abstract][Full Text] [Related]
48. Mutational analysis of the KIT gene in myelodysplastic syndrome (MDS) and MDS-derived leukemia.
Lorenzo F; Nishii K; Monma F; Kuwagata S; Usui E; Shiku H
Leuk Res; 2006 Oct; 30(10):1235-9. PubMed ID: 16533529
[TBL] [Abstract][Full Text] [Related]
49. The detection of wt-1 transcripts is not associated with an increased leukemic relapse rate in patients with acute leukemia after allogeneic bone marrow or peripheral blood stem cell transplantation.
Elmaagacli AH; Beelen DW; Trenschel R; Schaefer UW
Bone Marrow Transplant; 2000 Jan; 25(1):91-6. PubMed ID: 10654021
[TBL] [Abstract][Full Text] [Related]
50. Autologous stem cell transplantation in myelodysplastic syndromes.
de Witte T; Suciu S; Brand R; Muus P; Kröger N
Semin Hematol; 2007 Oct; 44(4):274-7. PubMed ID: 17961727
[TBL] [Abstract][Full Text] [Related]
51. Predictors of outcome following myeloablative allo-SCT for therapy-related myelodysplastic syndrome and AML.
Nevill TJ; Hogge DE; Toze CL; Nantel SH; Power MM; Abou Mourad YR; Song KW; Lavoie JC; Forrest DL; Barnett MJ; Shepherd JD; Nitta JY; Wong S; Sutherland HJ; Smith CA
Bone Marrow Transplant; 2008 Nov; 42(10):659-66. PubMed ID: 18679372
[TBL] [Abstract][Full Text] [Related]
52. Wilms tumor gene 1 expression as a predictive marker for relapse and survival after hematopoietic stem cell transplantation for myelodysplastic syndromes.
Yoon JH; Jeon YW; Yahng SA; Shin SH; Lee SE; Cho BS; Lee DG; Eom KS; Kim HJ; Lee S; Min CK; Cho SG; Kim Y; Kim DW; Lee JW; Han K; Min WS; Park CW; Kim M; Kim YJ
Biol Blood Marrow Transplant; 2015 Mar; 21(3):460-7. PubMed ID: 25460359
[TBL] [Abstract][Full Text] [Related]
53. Minimal residual disease testing to predict relapse following transplant for AML and high-grade myelodysplastic syndromes.
Wertheim GB; Bagg A
Expert Rev Mol Diagn; 2011 May; 11(4):361-6. PubMed ID: 21545254
[TBL] [Abstract][Full Text] [Related]
54. [Clinical experience of 19 patients with myelodysplastic syndrome (MDS)].
Makino S; Araki Y; Tamura K; Seita M; Torigoe J; Kawachi J
Rinsho Ketsueki; 1988 Feb; 29(2):116-22. PubMed ID: 3164422
[No Abstract] [Full Text] [Related]
55. [WT1 peptide-based immunotherapy].
Sugiyama H
Nihon Rinsho; 2005 Jun; 63(6):1101-9. PubMed ID: 15948398
[TBL] [Abstract][Full Text] [Related]
56. [Expression of WT1 gene in patients with myelodysplastic syndrome and acute leukemia].
Lu Y; Jin J; Xu WL
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2004 Aug; 12(4):464-6. PubMed ID: 15363132
[TBL] [Abstract][Full Text] [Related]
57. WT1 as a universal marker for minimal residual disease detection and quantification in myeloid leukemias and in myelodysplastic syndrome.
Cilloni D; Saglio G
Acta Haematol; 2004; 112(1-2):79-84. PubMed ID: 15179007
[TBL] [Abstract][Full Text] [Related]
58. Successful Allogenic Haematopoietic Stem Cell Transplantation in a Boy with Hemophilia A and MDS-RAEB.
Reimann C; van Buiren M; Schelling J; Halimeh S; Niehues T; Strahm B; Zieger B
Klin Padiatr; 2016 Nov; 228(6-07):336-338. PubMed ID: 27571289
[No Abstract] [Full Text] [Related]
59. [Myelodysplastic syndrome (RAEB in T) developed in a renal allograft recipient].
Shiraishi J; Sudo Y; Katori Y; Akiyama M; Takada O; Maki K; Sawada K; Inaba T; Shimazaki C; Nakagawa M
Rinsho Ketsueki; 1998 Aug; 39(8):600-5. PubMed ID: 9785979
[TBL] [Abstract][Full Text] [Related]
60. Marked thrombocytosis in a child with advanced myelodysplastic syndrome.
Claviez A; Ngoumou B; Harder L; Baumann I; Niemeyer C
Leuk Lymphoma; 2004 Apr; 45(4):849-50. PubMed ID: 15160971
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
